SHPG - Shire plc

NasdaqGS - NasdaqGS Delayed Price. Currency in USD
158.37
-5.56 (-3.39%)
At close: 4:00PM EDT

161.50 +3.13 (1.98%)
Pre-Market: 8:21AM EDT

Stock chart is not supported by your current browser
Previous Close163.93
Open164.60
Bid161.22 x 1200
Ask161.40 x 300
Day's Range157.69 - 164.80
52 Week Range123.73 - 192.15
Volume4,023,173
Avg. Volume1,497,400
Market Cap46.929B
Beta1.47
PE Ratio (TTM)11.28
EPS (TTM)14.04
Earnings DateN/A
Forward Dividend & Yield1.05 (0.64%)
Ex-Dividend Date2018-03-08
1y Target Est197.42
Trade prices are not sourced from all markets
  • Texas Instruments, Shire and Wynn Resorts are the Yahoo charts of the day
    Yahoo Finance Video22 hours ago

    Texas Instruments, Shire and Wynn Resorts are the Yahoo charts of the day

    Let's check out the Yahoo Finance charts of the day. Texas Instruments (TXN): Shares are higher in early trade, up around 3%. The chipmaker reported adjusted quarterly profit of $1.21 per share, 10 cents a share above consensus forecasts. The company also forecast stronger than expected earnings for the current quarter. Shire (SHPG): Shares down around 0.52%. The biopharmaceutical company said it was willing to recommend the latest takeover bid from Japan's Takeda Pharmaceutical, after rejecting four other bids, Takeda is now offering $64 billion for the British drug maker. Wynn Resorts (WYNN): Shares slip down around 3.4%. The company posting adjusted quarterly earnings of $2.30 per share, beating estimates by 32 cents a share. The casino operator's revenue was slightly below forecasts. Wynn also increased it's quarterly dividend to 75 cents per share from 50 cents. For more on today's big stock movers check out The Final Round, live at 3:55 p.m. ET, right here on Yahoo Finance.

  • Texas Instruments jumps, Shire goes higher, Wynn Resorts slip
    Yahoo Finance20 hours ago

    Texas Instruments jumps, Shire goes higher, Wynn Resorts slip

    Texas Instruments, Shire and Wynn Resorts are the Yahoo charts of the day.

  • Bid target Shire grows earnings six percent, holds cautious outlook
    Reuters35 minutes ago

    Bid target Shire grows earnings six percent, holds cautious outlook

    Shire (SHP.L), the London-listed drugmaker targeted by Takeda Pharmaceutical , reported a 6 percent rise in first-quarter earnings on Thursday, while keeping its cautious outlook for the year in the face of increasing drug competition. Shire is willing to recommend a $64 billion (46 billion pounds) offer from Takeda to shareholders, in what would be the biggest acquisition of a drug company since 2000, but investors see risks to the ambitious deal being consummated. Currency factors flattered Shire sales in the quarter as Shire felt the impact of falling sales of its flagship ulcerative colitis drug Lialda.

  • Financial Times35 minutes ago

    [$$] Shire Q1 sales rise 7% driven by immunology and new treatments

    , the life sciences specialist currently considering a takeover proposal from Japan’s Takeda, saw overall sales rise by 7 per cent year-on-year in the first quarter on the back of immunology, recently-launched products and overseas expansion. The company, which has agreed a deadline of May 8 by which Takeda must make its intentions known under UK takeover rules, said sales had been $3.6bn in the first three months of this year. Mr Ornskov has set a goal of between $17bn and $18bn in annual sales by 2020.

  • GlobeNewswire1 hour ago

    Shire plc : 1st Quarter Results

      Shire Delivers 7% Product Sales Growth and Robust Pipeline Progress in Q1 2018   Growth driven by Immunology, recently-launched products, and international expansion   Innovative pipeline progresses ...

  • GlobeNewswire6 hours ago

    Shire plc : Rule 2.9 Announcement

    NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. ...

  • The Wall Street Journal8 hours ago

    [$$] Takeda Nears Shire Deal as Japanese Companies Chase Growth Overseas

    Takeda is near a deal worth more than $60 billion to buy European drugmaker Shire, having raised its bid four times in a sign of how ardently Japan’s legacy companies are pursuing growth abroad as sales ...

  • Shire Says It's Willing To Entertain $64 Billion Bid From Takeda Pharma
    Investor's Business Daily15 hours ago

    Shire Says It's Willing To Entertain $64 Billion Bid From Takeda Pharma

    Shire said late Tuesday it's willing to recommend a $64 billion takeover by Takeda Pharmaceuticals to shareholders before a new May 8 deadline.

  • Takeda Pharmaceutical Makes 4th Successive Bid for Shire
    Market Realist18 hours ago

    Takeda Pharmaceutical Makes 4th Successive Bid for Shire

    Takeda Pharmaceutical’s (TKPYY) bid for Shire (SHPG) has piqued a lot of investor interest. After three of Takeda’s previous bids were rejected, it announced a new bid of $60 billion for Shire on April 20. Takeda, a Japanese pharmaceutical company, has increased its offer to 47 pounds per share from 46.5 pounds per share.

  • Moody's19 hours ago

    Shire Acq Inv Ireland Designated Activity Co -- Moody's: An acquisition of Shire by Takeda could have positive or negative implications for Shire

    Moody's Investors Service commented that an acquisition of Shire plc ("Shire") by Takeda Pharmaceutical Company Limited ("Takeda") could have either positive or negative implications for Shire's credit profile. Shire is rated Baa3 with a positive rating outlook. There is no impact on Shire's ratings or outlook at this time.

  • Shire willing to back $64 billion Takeda bid, market signals doubts
    Reuters20 hours ago

    Shire willing to back $64 billion Takeda bid, market signals doubts

    LONDON/NEW YORK/TOKYO (Reuters) - Rare disease specialist Shire said on Wednesday it was willing to recommend a sweetened $64 billion offer from Japan's Takeda Pharmaceutical Co to shareholders, in what would be the biggest acquisition of a drug company since 2000. The stock slide - 18 percent since the news of a possible bid broke - makes the cash-and-share deal less appealing to Shire shareholders, some of whom may be reluctant or unable to hold Takeda shares. "The chances are UK shareholders in particular are not going to want Takeda shares, so there’s going to be a forced discount because some people are going to sell it," said Neil Dwane, global strategist at Allianz Global Investors, which holds 1.1 percent of Shire, Thomson Reuters data showed.